← Search & browse all drugs
VARIOUS › CONTRAST MEDIA › ULTRASOUND CONTRAST MEDIA › Ultrasound contrast media
perflubutane, phospholipid microspheres
V08DA06
Forms & Strengths
- Injectable suspension: perflubutane lipid microspheres provided as lyophilized powder in a vial with a separate diluent vial for reconstitution
- Concentration after reconstitution: approximately 2 x 10^9 microspheres/mL containing 1.2 mg/mL perflubutane gas
Adult Dosing
- Echocardiography: 0.12 mL/kg (up to a maximum single injection of 10 mL) administered intravenously as an injection
- May repeat dose once if needed for diagnostic enhancement
- Flush IV line immediately with 5 mL of normal saline
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
Indications
- Indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Mechanism of Action
- Perflubutane phospholipid microspheres act as an ultrasound contrast agent
- The microbubbles oscillate and reflect ultrasound waves, increasing the echogenicity of blood and enhancing the delineation of the blood-tissue interface in the cardiac chambers
Contraindications
- Known hypersensitivity to perflubutane, lipid excipients, or any component of the product
- History of severe hypersensitivity reactions to perflubutane lipid microspheres
Adverse Reactions
- Headache
- Nausea
- Injection site pain
- Flushing
- Dizziness
- Serious cardiopulmonary reactions including anaphylaxis and fatal cardiac arrest (rare)
Drug Interactions
- No formal drug interaction studies have been conducted with perflubutane
- Caution when administering concurrently with other cardioactive drugs due to the potential for severe cardiopulmonary adverse reactions
Curated Content: Needs Vetting Before Put to Clinical Use